Overexpression of Eag1 potassium channels in clinical tumours. - Wikidata - wikimedia - TriplyDB

Overexpression of Eag1 potassium channels in clinical tumours.

Overexpression of Eag1 potassium channels in clinical tumours.

http://www.wikidata.org/entity/Q35107467

about

Eag and HERG potassium channels as novel therapeutic targets in cancer Ether à go-go potassium channel expression in soft tissue sarcoma patients Physical and functional interaction of KV10.1 with Rabaptin-5 impacts ion channel trafficking Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics Neuronal and Cardiovascular Potassium Channels as Therapeutic Drug Targets: Promise and Pitfalls Voltage-gated ion channels in cancer cell proliferation Structure of the voltage-gated K⁺ channel Eag1 reveals an alternative voltage sensing mechanism Eag1 channels as potential early-stage biomarkers of hepatocellular carcinoma Human EAG channels are directly modulated by PIP2 as revealed by electrophysiological and optical interference investigations Rapid internalization of the oncogenic K+ channel K(V)10.1 Astemizole synergizes calcitriol antiproliferative activity by inhibiting CYP24A1 and upregulating VDR: a novel approach for breast cancer therapy Chemical Library Screening and Structure-Function Relationship Studies Identify Bisacodyl as a Potent and Selective Cytotoxic Agent Towards Quiescent Human Glioblastoma Tumor Stem-Like Cells Functional K(v)10.1 channels localize to the inner nuclear membrane Absence of direct cyclic nucleotide modulation of mEAG1 and hERG1 channels revealed with fluorescence and electrophysiological methods External pH modulates EAG superfamily K+ channels through EAG-specific acidic residues in the voltage sensor Behavioural and functional characterization of Kv10.1 (Eag1) knockout mice DNA hypermethylation of tumors from non-small cell lung cancer (NSCLC) patients is associated with gender and histologic type.Silencing of Ether à go-go 1 by shRNA inhibits osteosarcoma growth and cell cycle progression Positive correlation between the expression of hEag1 and HIF-1α in breast cancers: an observational study.The potassium channel Ether à go-go is a novel prognostic factor with functional relevance in acute myeloid leukemia Transcriptional and post-transcriptional mechanisms for oncogenic overexpression of ether à go-go K+ channel.Targeting potassium channels in cancer Potassium channel ether à go-go1 is aberrantly expressed in human liposarcoma and promotes tumorigenesis Aberrant expression of ether à go-go potassium channel in colorectal cancer patients and cell lines.In vivo dual targeting of the oncogenic Ether-à-go-go-1 potassium channel by calcitriol and astemizole results in enhanced antineoplastic effects in breast tumors.The Eag potassium channel as a new prognostic marker in ovarian cancer.Regulation of hERG and hEAG channels by Src and by SHP-1 tyrosine phosphatase via an ITIM region in the cyclic nucleotide binding domain Differential Expression of Ion Channels and Transporters During Hepatocellular Carcinoma Development.Analysis of the expression of Kv10.1 potassium channel in patients with brain metastases and glioblastoma multiforme: impact on survival.Voltage-Gated K+ Channel, Kv3.3 Is Involved in Hemin-Induced K562 Differentiation.Temple-Baraitser Syndrome and Zimmermann-Laband Syndrome: one clinical entity?Tuning of EAG K(+) channel inactivation: molecular determinants of amplification by mutations and a small molecule Kcnh1 voltage-gated potassium channels are essential for early zebrafish development Alternatively Spliced Isoforms of KV10.1 Potassium Channels Modulate Channel Properties and Can Activate Cyclin-dependent Kinase in Xenopus Oocytes.Short Hairpin RNA (shRNA) Ether à go-go 1 (Eag1) inhibition of human osteosarcoma angiogenesis via VEGF/PI3K/AKT signaling.Expression of eag1 channel associated with the aggressive clinicopathological features and subtype of breast cancer.Expression of Eag1 K+ channel and ErbBs in human pituitary adenomas: cytoskeleton arrangement patterns in cultured cells p38 MAPK regulates the expression of ether à go-go potassium channel in human osteosarcoma cells.ICA-105574 interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and ERG potassium channels.MicroRNA-34a inhibits human osteosarcoma proliferation by downregulating ether à go-go 1 expression

P2860

Q21245576-75281FA8-26A0-4A88-B9BA-C59268578F25 Q21245739-C539470C-35B6-4C91-B8C1-12140F2FB0AB Q24294406-0F430377-E8B2-4163-816D-D2F379276A85 Q24294672-35C1FADB-F5DF-4F9A-84EF-D4E3949618DD Q26798018-052140A5-8C7D-4AEB-A9EE-EA8468EC4A10 Q27010511-04857175-00C8-424D-92EA-9EE9AA192E1A Q27727293-3EF732FE-5870-4FB2-A5DA-226BBF583C59 Q28069313-C891EF0A-2BBC-4506-87EA-94FBD87473BE Q28118681-1BF1FB5C-EB96-4BF0-8DF6-2EF1B368E781 Q28477472-F4875361-3BEF-42DF-BDBF-2C4A210A66F4 Q28483692-763B33B5-090D-4F66-A206-65790FB8D8F7 Q28547244-74E85207-AAD5-4992-92C2-00049B942395 Q28571386-E152E368-4D0D-4207-8857-F34B6327754A Q28591022-D8CB5A99-65C8-4CEC-BFEE-9B1106387727 Q30416079-7BC997FD-61CF-4777-9812-99B4F4151F7B Q30454673-4A32E086-0DC4-4359-AEB5-A03F054E5663 Q30494942-FA3B7179-6ADA-45BD-9A72-8774483AAC64 Q33580439-4AB650EC-59D0-4A0E-AAC3-4E5CCD5DE84F Q33629346-3E3BDB54-6322-43EC-8E44-E38785347A96 Q33715775-555DAD6D-3A31-4AF2-A7E4-6E0C091A1402 Q33927117-A414E5FD-CCBD-4EC6-8A1E-9C6D4BF01A6F Q33937726-7CFBCFE1-AD09-4DD8-87B9-64911CC71175 Q34022525-CEC61111-94FB-477C-80F9-981B8A44DAA8 Q34099591-4A4D4906-2E59-4BB6-B050-559E545BC752 Q34325900-01336731-DEDE-4466-9190-92B35B6AFEEE Q34468285-DC204FAA-5550-4881-A78B-9961D7211031 Q35108594-CB91FE8F-A0E5-49AF-A33C-23542E4B7C0E Q35595247-9C5956C3-86BE-4848-ACE8-228B185A06E3 Q35830894-116930B0-8862-4AEA-9A81-6E5D60BF2FEB Q35915910-EB623B67-62B5-4AD6-AD0A-6B393CA4DAE9 Q36047304-C00FACEF-D7C7-4718-B781-5EA13745FEF8 Q36209596-F6C5D57A-B325-42C4-A439-B3853BEA32CB Q36318808-540187A2-570A-439A-A2B4-EDF0774F0F85 Q36381917-64CCA534-3B2F-4259-AD77-4D149B03EBF4 Q36396465-E8C4DFD6-1AE6-40D2-8894-FEE0C5BD40E3 Q36464823-D935B564-8B56-4C17-8F48-6ED1E543ED33 Q36584340-A54BD99A-3BF2-4C1D-B783-5D52A600F525 Q36613887-90F4E420-FE6A-46F1-8DBC-6863AE644B80 Q36717056-BD733464-073D-4FFE-8CE7-7B8B897D9491 Q36746921-D71512F7-C284-497B-B89F-4060F4CF2BFD

P2860

Overexpression of Eag1 potassium channels in clinical tumours.

http://www.wikidata.org/entity/Q35107467

description

2006 nî lūn-bûn

@nan

2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Overexpression of Eag1 potassium channels in clinical tumours.

@ast

Overexpression of Eag1 potassium channels in clinical tumours.

@en

type

label

Overexpression of Eag1 potassium channels in clinical tumours.

@ast

Overexpression of Eag1 potassium channels in clinical tumours.

@en

prefLabel

Overexpression of Eag1 potassium channels in clinical tumours.

@ast

Overexpression of Eag1 potassium channels in clinical tumours.

@en

P1433

Q35107467-C6637269-3CB3-4A62-8F12-BE12AEE70118

P1476

Q35107467-57D45C63-2B49-445E-BCAE-A091AF23225E

P2093

Q35107467-1F3C9240-9A6D-4E3D-A6C3-BDE147A2DE22

Q35107467-261E1DFB-887D-4EDB-AA73-9BC1B542362C

Q35107467-367DB924-9A67-4A1F-AC52-0517EAB37DA1

Q35107467-379BF023-96F2-4654-A035-689292C229DF

Q35107467-803602BA-FE97-4562-90C3-8194DF4B37D0

Q35107467-81D1B0D2-2C89-41CB-8337-FF2FFC96A387

Q35107467-946FF863-E2EF-4660-A09A-B547DED874F2

Q35107467-D6DA2E0C-538D-4BDC-9C13-2E925849E874

Q35107467-D91F9AB4-0893-45EB-81B2-034BBDC62C24

Q35107467-D96722B0-F3B1-42FA-9108-6CC73E7C4D2F

P2860

Q35107467-0CAC1FD1-BD04-4C52-B36E-3F904C676C9F

Q35107467-0E090B24-AC70-4AEF-A907-0BDCA06557E7

Q35107467-0F937C02-68A9-425D-B74D-AB6FCF1E315C

Q35107467-15C5CB9D-4F40-4F47-8801-9228BBCD1EFB

Q35107467-23209F0F-B027-49E6-8FFC-A582D39F60AB

Q35107467-2AA4AECE-A0E4-4AC5-9851-881281050E5A

Q35107467-3BDE18CF-9D86-4272-AE09-ECABB2805B37

Q35107467-3C517616-AB02-46EB-B31A-B2585FB14718

Q35107467-3E6E70E2-639D-4D35-B14A-130B5F3091A1

Q35107467-3EBB56B5-265A-4EA0-A85E-E080A6808AE5

P2888

Q35107467-420EA415-CF1C-48C1-807F-DFBDB2E6DF2B

P304

Q35107467-6E0D2521-7734-4518-AE95-E96B7C7CFBB9

P31

Q35107467-EA50EFFC-10E9-4865-B73A-6148DBA1B1D3

P356

Q35107467-499BF7E1-2924-407A-AB1F-F3EC9755A4E0

P478

Q35107467-22E8BA4C-A0D2-4EC3-BE45-F433BF656B8E

P50

Q35107467-BB0295CB-698B-4257-872C-60FB835F390B

P577

Q35107467-D89ED5FD-186C-4B47-814A-7ECFB2E29D2F

P5875

Q35107467-74EF6D2C-9947-4778-B286-EBADDB18728D

P6179

Q35107467-20024914-47FC-4F40-BE4F-EA3892A9C2B3

P698

Q35107467-B58CD8FB-913D-4D50-8010-DA89A999ABF9

P921

Q35107467-E30DE3BC-D5C0-4A72-A9F6-ABE7E5045465

P932

Q35107467-47FD359C-E34E-417D-98EE-9FD1FF372AD5

P356

P1433

Molecular Cancer

P1476

Overexpression of Eag1 potassium channels in clinical tumours

@en

P2093

Araceli Sánchez

http://www.w3.org/2001/XMLSchema#string

Bernhard Hemmerlein

http://www.w3.org/2001/XMLSchema#string

Fernanda Mello de Queiroz

http://www.w3.org/2001/XMLSchema#string

Heinz-Joachim-Radzun

http://www.w3.org/2001/XMLSchema#string

Hendrik Knötgen

http://www.w3.org/2001/XMLSchema#string

Marc Jenke

http://www.w3.org/2001/XMLSchema#string

María E Rubio

http://www.w3.org/2001/XMLSchema#string

Rüdiger M Weseloh

http://www.w3.org/2001/XMLSchema#string

Sabine Martin

http://www.w3.org/2001/XMLSchema#string

Tessa Schliephacke

http://www.w3.org/2001/XMLSchema#string

P2860

Ether à go-go potassium channel expression in soft tissue sarcoma patients

Cloning of a human ether-a-go-go potassium channel expressed in myoblasts at the onset of fusion

Oncogenic potential of EAG K(+) channels

A family of potassium channel genes related to eag in Drosophila and mammals

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Molecular identification and characterisation of the human eag2 potassium channel

Regulation of an ERG K+ current by Src tyrosine kinase

The NCIC-Manitoba Breast Tumor Bank: a resource for applied cancer research

Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli

Human tumor antigens: implications for cancer vaccine development.

P2888

P304

41

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1476-4598-5-41

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-10-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6771863

http://www.w3.org/2001/XMLSchema#string

P6179

1040572249

http://www.w3.org/2001/XMLSchema#string

P698

17022810

http://www.w3.org/2001/XMLSchema#string

P921

P932

1621079

http://www.w3.org/2001/XMLSchema#string